Drug Profile
PF 4308515
Alternative Names: PF-04308515; PF-4308515Latest Information Update: 02 Mar 2012
Price :
$50
*
At a glance
- Originator Pfizer
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 28 Feb 2012 Discontinued - Phase-I for Inflammation in USA (PO)
- 30 Apr 2010 Pfizer initiates enrolment in a phase I trial (multiple-dose escalation) for Inflammation in the US